<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866771</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0097</org_study_id>
    <nct_id>NCT04866771</nct_id>
  </id_info>
  <brief_title>Remotely Supervised tDCS for Slowing ALS Disease Progression</brief_title>
  <official_title>Remotely Supervised Transcranial Direct Current Stimulation for Slowing Disease Progression in Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most ALS care is centered on patient support and symptom management, making rehabilitation an&#xD;
      integral aspect for slowing disease progression, prolonging life span, and increasing quality&#xD;
      of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool&#xD;
      to prime motor function in several neurological disorders. We propose a novel mechanism using&#xD;
      remotely supervised brain stimulation to preserve motor function in individuals with ALS.&#xD;
      This project will also aim to explore the effectiveness of brain stimulation on upper and&#xD;
      lower motor neuron mechanisms in individuals with ALS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revised ALS Functioning Rating Scale (ALSFRS-R)</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>This questionnaire evaluates function over time and disease progression in ALS patients with questions related to daily activities such as speech, swallowing, walking, etc. Scores range between 0-40 with higher scores corresponding to more function being retained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Strength Testing</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Maximum strength of bilateral ankle dorsiflexors and knee extensors will be tested using a hand-held dynamometer and using the Medical Research Council (MRC) Scale for muscle strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gait speed</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Self-selected and fast walking will be measured as the average walking speed from 2 trials of the 10-m walk test (10MWT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-meter walk</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>The 10-meter walk test (10MWT) is a performance measure used to assess walking speed in meters per second over a short distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle motor control</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>The participant will track a computer-generated sinusoidal target with ankle dorsiflexion and plantarflexion in a custom-built ankle-tracking device. Accuracy of tracking the target with ankle motion will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life with EuroQol-5D (EQ-5D)</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Quality of life will be measured with the EuroQol-5D (EQ-5D), a questionnaire with questions designed to assess aspects of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQual-Visual Analog Scale (EQ-VAS)</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Quality of life will be measured using a visual analog scale with endpoints labeled, 'The best health you can imagine' and 'the worst health you can imagine' in response to questions related to aspects of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>9-item scale measuring severity of fatigue and its effect on participant's daily activities and lifestyle with higher scores representing more fatigue and fatigue playing a larger role in daily activities. Minimum score = 0 and maximum score = 63.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper and lower motor neuron mechanisms using transcranial magnetic stimulation (TMS)</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Upper and lower motor neuron mechanisms of the tibialis anterior will be measured using single pulse transcranial magnetic stimulation (TMS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper and lower motor neuron mechanisms using peripheral nerve stimulation (PNS)</measure>
    <time_frame>Change from baseline to immediately after training and baseline to 3 months follow up.</time_frame>
    <description>Upper and lower motor neuron mechanisms in ALS will also be assessed using peripheral nerve stimulation at either the knee or the elbow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facilitatory transcranial direct current stimulation (tDCS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS followed by a switch to anodal tDCS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation (tDCS)</intervention_name>
    <description>Noninvasive brain stimulation</description>
    <arm_group_label>Transcranial Direct Current Stimulation (tDCS)</arm_group_label>
    <other_name>Soterix Medical 1X1 tDCS mini-CT Stimulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham tDCS + anodal tDCS</intervention_name>
    <description>Fake noninvasive brain stimulation or anodal noninvasive brain stimulation</description>
    <arm_group_label>Delayed-Start Transcranial Direct Current Stimulation (tDCS) Control Group</arm_group_label>
    <other_name>Soterix Medical 1X1 tDCS mini-CT Stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of definite amyotrophic lateral sclerosis according to El Escorial revised&#xD;
             criteria&#xD;
&#xD;
          -  Spinal onset ALS with initial weakness in the upper or lower extremity.&#xD;
&#xD;
          -  Diagnosed with ALS within the past 24 months&#xD;
&#xD;
          -  1-2 point change in pre-slope of the ALSFRS-R at time of enrollment (ratio of drop in&#xD;
             score from 48 to the duration in months from onset of weakness)&#xD;
&#xD;
          -  Slow vital capacity greater than or equal to 40% of predicted value&#xD;
&#xD;
          -  Score ≥ 2 for &quot;swallowing&quot; of the ALSFRS-R&#xD;
&#xD;
          -  Score ≥ 2 for &quot;walking&quot; of the ALSFRS-R&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Stable dose of riluzole or edaravone or no medications&#xD;
&#xD;
          -  Availability of a caregiver for remote administration of tDCS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has bulbar onset ALS&#xD;
&#xD;
          -  Any neurological diagnosis other than ALS&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Any other concomitant disease that affects prognosis of ALS inclusive of systemic&#xD;
             disease, cardiovascular disease, hepatic or renal disorder&#xD;
&#xD;
          -  Tracheostomal or noninvasive ventilation for more than 12 hours per day&#xD;
&#xD;
          -  Enrollment in an on-going ALS pharmaceutical trial&#xD;
&#xD;
          -  Subject plans on moving within 3 months.&#xD;
&#xD;
        TMS Exclusion Criteria:&#xD;
&#xD;
          -  Implanted cardiac pacemaker&#xD;
&#xD;
          -  Metal implants in the head or face&#xD;
&#xD;
          -  Unexplained, recurring headaches&#xD;
&#xD;
          -  History of seizures or epilepsy&#xD;
&#xD;
          -  Currently under medication that could increase motor excitability and lower seizure&#xD;
             threshold&#xD;
&#xD;
          -  Skull abnormalities or fractures&#xD;
&#xD;
          -  Concussion within the last 6 months&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  tDCS Exclusion Criteria:&#xD;
&#xD;
          -  Skin hypersensitivity&#xD;
&#xD;
          -  History of contact dermatitis&#xD;
&#xD;
          -  History of allodynia and/or hyperalgesia&#xD;
&#xD;
          -  Any other skin or scalp condition that could be aggravated by tDCS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangeetha Madhavan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangeetha Madhavan, PT, PhD</last_name>
    <phone>312-355-2517</phone>
    <email>smadhava@uic.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brain Plasticity Lab</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangeetha Madhavan</last_name>
      <email>smadhava@uic.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sangeetha Madhavan</investigator_full_name>
    <investigator_title>Associate Professor, Physical Therapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

